State-of-the-art surgical management of testicular tumors

References

• American Cancer Society. Cancer Facts and Figures, 2005.American Cancer Society, Atlanta, GA, USA (2005).
   Google Scholar
• Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J. Urol.170(1), 5–11 (2003).
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J. Clin.53, 5–26 (2003).
   PubMed Web of Science ®Google Scholar
• Donohue JP. Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection. Urol. Clin. North Am.4, 509–521 (1977).
   PubMedGoogle Scholar
• Jewett MA. Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol. Clin. North Am.17, 449–456 (1990).
   PubMed Web of Science ®Google Scholar
• Javadpour N. Significance of elevated serum alpha fetoproteins [AFP] in seminoma. Cancer45, 2166–2168 (1980).
   PubMed Web of Science ®Google Scholar
• Boyle LE, Samuels ML. Serum LDH activity and isoenzyme patterns in nonseminomatous germinal [NSG] testis tumors. Proc. Am. Soc. Clin. Oncol.18, 278 (1977).
   Google Scholar
• Stomper PC, Jochelson MS, Garnick MB, Richie JP. Residual abdominal masses following chemotherapy for nonseminomatous testicular cancer: correlation of CT and histology. AJR Am. J. Roentgenol.145, 743–746 (1985).
   PubMed Web of Science ®Google Scholar
• Ganjoo KN, Chan RJ, Sharma M, Einhorn LH. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J. Clin. Oncol.17, 3457–3460 (1999).
   PubMed Web of Science ®Google Scholar
• Weinstein M. Lymphatic drainage of the testes. Atlas Urol. Clin. North Am.7, 1–7 (1999).
   Google Scholar
• Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J. Urol.128, 315–320 (1982).
   PubMed Web of Science ®Google Scholar
• Sogani PC. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Urol. Clin. North Am.18, 561–573 (1991).
   PubMed Web of Science ®Google Scholar
• Whitmore W. Some experiences with retroperitoneal lymph node dissections and chemotherapy in the management of testis neoplasms. Br. J. Urol.34, 436–447 (1962).
   Google Scholar
• Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J. Clin. Oncol.9, 1393–1396 (1991).
   PubMed Web of Science ®Google Scholar
• Sheinfeld J, Rentzepis M, Leon A. Prognostic factors of clinical outcome and extent of postoperative chemotherapy in patients with high volume [pN2/N3] nodal disease following 1° RPLND for nonseminomatous germ cell tumor [NSGCT]. J. Urol.161, 606A (1999).
   PubMed Web of Science ®Google Scholar
• Whitmore W. Some experiences with retroperitoneal lymph node dissections and chemotherapy in the management of testis neoplasms. Br. J. Urol.34, 436–447 (1962).
   Google Scholar
• Skinner DG. Non-seminomatous testis tumors: a plan of management based in 96 patients to improve survival in all stages by combined therapeutic modalities. J. Urol.115, 65–69 (1976).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Thornhill JA, Foster RS et al. Retroperitoneal lymphadenectomy for clinical stage A testis cancer [1965 to 1989]: modifications of technique and impact on ejaculation. J. Urol.149, 237–243 (1993).
   PubMed Web of Science ®Google Scholar
• Baniel J, Foster RS, Rowland RG. Complications of primary retroperitoneal lymph node dissection. J. Urol.152, 424–427 (1994).
   PubMed Web of Science ®Google Scholar
• Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J. Urol.127, 685–688 (1982).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Foster RS, Rowland RG. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J. Urol.144, 287–291 (1990).
   PubMed Web of Science ®Google Scholar
• Richie JP. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J. Urol.144, 1160–1163 (1990).
   PubMed Web of Science ®Google Scholar
• Eggener SE, Carver BS, Sharp DS, Motzer RJ, Bosl GJ, Sheinfeld J. Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer. J. Urol.177(3), 937–942 (2007).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer83, 1002–1011 (1998).
   PubMed Web of Science ®Google Scholar
• Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HT, Bosl G. Clinical stage I testis cancer – long-term outcome of patients on surveillance. J. Urol.159, 855–858 (1998).
   PubMed Web of Science ®Google Scholar
• Hermans BP, Sweeney CJ, Foster RS, Einhorn LE, Donohue JP. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J. Urol.163, 1721–1724 (2000).
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Bosl GJ, Motzer RJ et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J. Clin. Oncol.23(12), 2781–2788 (2005).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Stage I nonseminomatous germ-cell testicular cancer management options and risk-benefit considerations. World J. Urol.12, 170–177 (1994).
   PubMed Web of Science ®Google Scholar
• Baniel J, Foster RS, Einhorn LH, Donohue JP. Late relapse of clinical stage I testicular cancer. J. Urol.154, 1370–1372 (1995).
   PubMed Web of Science ®Google Scholar
• Amato RJ, Ro JY, Ayala AG, Swanson DA. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology63, 144–148 (2004).
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J. Urol.174(2), 557–560 (2005).
   PubMed Web of Science ®Google Scholar
• Pohar KS, Rabbani F, Bosl GJ. Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J. Urol.170, 1155–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Hermans BP, Heilman DK. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma-predominant testis cancer. J. Clin. Oncol.18, 358–362 (2000).
   PubMed Web of Science ®Google Scholar
• Sheinfeld J, Motzer RJ, Rabbani F. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIa nonseminomatous germ cell tumors. J. Urol.170, 1159–1162 (2003).
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Albers P, Hartmann M, Kliesch S. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J. Urol.169(5), 1710–1714 (2003).
   PubMed Web of Science ®Google Scholar
• Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N. Engl. J. Med.337, 242–254 (1997).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J. Urol.153(1), 85–89 (1995).
   PubMed Web of Science ®Google Scholar
• Rabbani F, Sheinfeld J, Farivat-Mohseni H, Leon A, Rentzepis MJ, Reuter VE. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J. Clin. Oncol.19, 2020–2025 (2001).
   PubMed Web of Science ®Google Scholar
• Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer – a long-term update. Urology62, 324–327 (2003).
   PubMed Web of Science ®Google Scholar
• Janetschek G, Hobisch A, Peschel R, Bartsch G. Laparoscopic retroperitoneal lymph node dissection. Urology55, 136–140 (2000).
   PubMed Web of Science ®Google Scholar
• Janetschek G, Reissigl A, Peschel R et al. Laparoscopic retroperitoneal lymphadenectomy in the pig – initial report. J. Endourol.7, 243–247 (1993).
   PubMed Web of Science ®Google Scholar
• Janetschek G, Reissigl A, Peschel R, Hobisch A, Bartsch G. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminmatous testicular tumor. Urology44, 382–391 (1994).
   PubMed Web of Science ®Google Scholar
• Gerber GS, Rukstalis DB, Bissada NK et al. Laparoscopic retroperitoneal lymphadenectomy: multi-institutional analysis. J. Urol.151(Pt 2), 461 (1994).
   Google Scholar
• Rassweiler J, Seemann O, Henkel TO. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations. J. Urol.156(3), 1108–1113 (1996).
   PubMed Web of Science ®Google Scholar
• Steiner H, Peschel R, Janetschek G et al. Long-term results of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology63(3), 550–555 (2004).
   PubMed Web of Science ®Google Scholar
• Janetschek G, Hobisch A, Hittmair A, Holtl L, Peschel R, Bartsch G. Laparoscopic retroperitoneal lymphadenectomy after chemotherapy for stage IIB nonseminomatous testicular carcinoma. J. Urol.161(2), 477–481 (1999).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Einhorn LH, Williams SD. Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. J. Urol.123, 876–880 (1980).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Leviovitch I, Foster RS, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin. Urol. Oncol.16, 65–71 (1998).
   PubMedGoogle Scholar
• Steyerberg EW, Gerl A, Fossa SD. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J. Clin. Oncol.16, 269–274 (1998).
   PubMed Web of Science ®Google Scholar
• Patel MI, Beck S, Bosl GJ, Motzer R, Bajorin D, Sheinfeld J. Histology of good risk non-seminomatous germ cell tumor patients following postchemotherapy retroperitoneal lymph node dissection after four cycles of etoposide and cisplatin. J. Urol.169, 681 (2003).
   Google Scholar
• Fox EP, Weathers TD, Williams SD. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J. Clin. Oncol.11, 1294–1299 (1993).
   PubMed Web of Science ®Google Scholar
• Donohue JP, Rowland RG, Kopecky K. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J. Urol.137, 1176–1179 (1987).
   PubMed Web of Science ®Google Scholar
• Steyerberg EW, Keizer HJ, Fossa SD. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J. Clin. Oncol.13, 1177–1187 (1995).
   PubMed Web of Science ®Google Scholar
• Vergouwe Y, Steyerberg EW, Foster RS, Habbema JD, Donohue JP. Validation of a prediction model and its predictors for the histology of residual masses in nonseminomatous testicular cancer. J. Urol.165, 84–88 (2001).
   PubMed Web of Science ®Google Scholar
• Herr HW, Sheinfeld J, Puc HS, Heelan R. Surgery for a post-chemotherapy residual mass in seminoma. J. Urol.157(3), 860–862 (1997).
   PubMed Web of Science ®Google Scholar
• De Santis M, Becherer A, Bokemeyer C. FDG-PET as prognostic indicator for seminoma residuals – an update from the multicenter SEMPET study. Proc. Am. Soc. Clin. Oncol.22 (2003) (Abstract 1535).
   PubMed Web of Science ®Google Scholar